resistance, page-39

Hi Outawater,

I totally agree with your post and the increasing resistance towards tamiflu is certainly MORE important to us shareholders then the ASX200.

At the end of the day its the Cash that Biota receives from the Royalties, that will be the driver, to where the company and shareprice is going, hence we are in the ASX200.

I have been saying in my previous post that I believe that in the next 6 to 12 months Tamilfu could become useless as a first line in defence against Swineflu, as it is now already against the common flu.

This will be HUGE for Biota, and GSK will certainly make hay while the sun shines imho, and up the production of Relenza wherever and whenever it can, to fullfill the many orders, to replace the by now, useless Tamiflu stock piles.

In such a situation it makes sense to fast track Laninamavir as well, so we will have at least again more then JUST ONE Antiviral, for the first line in defence strategie.

If you all just sit back, and let this sink in, ALL THOSE BILLIONS IN TAMIFLU SALES that went to Roche, will now go to GSK and the ROYALTIES WILL FLOW TO BIOTA.

First from Relenza and then, or even together for the last few years before the Relenza Patent expirers , from Lani.

I may be dreaming but with all the resistance cases showing up and the increase of speed that this happens, it is not too far fetched to see this scenario from happening.

And if this is going to happen THEN WE WILL GET OUR 2 BILLION DOLLAR MARKET CAP for BIOTA, and a share price of $10 plus per share.

Nothing is impossible and if you smell that you are on a winner , hang in there, because the do not come often along.

The Bots will be working overtime and the more they do, the more YOU know that Something is UP.

Good luck guys

And yes you are right , I am excited and think outawater is hitting the nail on its head, WE are ON A WINNER WITH BIOTA>

jojo